GAITHERSBURG, Md., July 30 (Reuters) - GlaxoSmithKline Plc's <GSK.N> <GSK.L> diabetes drug Avandia should stay on the U.S. market even though data suggest it may raise the risk of a heart attack for some patients, an advisory panel said on Monday.

The Food and Drug Administration will consider the recommendation from outside experts but usually follows their advice.

AlertNet news is provided by